IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
Launched by FUDAN UNIVERSITY · Apr 11, 2011
Trial Information
Current as of May 06, 2025
Unknown status
Keywords
ClinConnect Summary
The standard treatment in patients with refractory or relapsed Hodgkin lymphoma is salvage chemotherapy followed by autologous transplantation for responsive patients. However, the standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy and safety of IGEV regimen in a single-center basis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age range: 18-65 years old
- • Histological confirmed refractory or relapsed Hodgkin lymphoma
- • With at least one site of measurable disease according to IWC criteria
- • ECOG performance status 0-1
- • Life expectancy of more than 3 months
- • Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L
- • Liver function: total bilirubin, ALT and AST \<1.5×UNL
- • Renal function: Cr\<1.5×UNL, CCR≧45ml/min
- • No contraindication for transplantation
- Exclusion Criteria:
- • No prior chemotherapy
- • With more than 2 lines of prior chemotherapy exposure
- • Evidence of CNS and bone marrow involvement
- • History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
- • Pregnant or lactating women
- • Significant active infection
About Fudan University
Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Ye Guo, MD
Principal Investigator
Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials